Lidocaine
Active ingredient · 7 therapeutic classes
Sold as Terocin · Trubrexa · MediNumb · Fortacin · Senstend
- Drug class
- Antiarrhythmics, Class Ib
- Availability
- Prescription and OTC
- Routes
- Topical, Epidural, Infiltration, Intracaudal, Intra-Articular
- Markets covered
- 4
- Products on record
- 269
- FDA reports (12 mo)
- 5,184
Overview
Plain-language summary, compiled from the cited regulatory records
Lidocaine is an antiarrhythmic medication belonging to Class Ib [1]. It is approved for producing anesthesia of accessible mucous membranes of the oropharynx [1]. Lidocaine is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites [1].
This medication is available under various brand names, including DCH Nerve Pain Relief, DCH Rapid Relief Hemorrhoidal, and Gen7T Plus [1]. In the past 12 months, there have been 5,184 adverse event reports associated with lidocaine [2]. The most frequently reported reactions include "Drug Ineffective," "Off Label Use," "Nausea," "Headache," and "Fatigue" [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 109 | May 18, 2026 |
| GB United Kingdom | MHRA | 99 | May 22, 2026 |
| CA Canada | Health Canada | 60 | May 29, 2026 |
| EU European Union | EMA | 1 | February 3, 2025 |
USUnited States· FDA
109 products
Uses
INDICATIONS AND USAGE
Lidocaine is indicated for the production of topical anesthesia of irritated or inflamed mucous membranes of the mouth and pharynx. It is also useful for reducing gagging during the taking of X-ray pictures and dental impressions.
How to take
GBUnited Kingdom· MHRA
99 products
Uses
General This product is non-sterile and therefore not recommended for use prior to procedures that require aseptic techniques.
For the prevention of pain associated with the following procedures:
Otorhinolaryngology Anaesthesia prior to minor non-invasive procedures in the nasal cavity, pharynx and epipharynx including rhinoscopy and laryngoscopy. Obstetrics As supplementary pain control for procedures not requiring aseptic technique.
Insertion of instruments and catheters into the respiratory and digestive tract Provides surface anaesthesia for the oropharyngeal and tracheal areas to reduce reflex activity, attenuate haemodynamic response and to facilitate insertion of the catheter or the passage of instruments during endotracheal intubation, laryngoscopy, bronchoscopy, oesophagoscopy and gastroscopy.
Dental practice Before minor dental procedures where local anaesthesia is desired.
CACanada· Health Canada
60 products
Uses
XYLOCAINE
g. g. g. proctoscopy, sigmoidoscopy, cystoscopy, endotracheal intubation. 1 DOSAGE AND ADMINISTRATION, Special Populations).
Pediatrics (<2 years of age):
Lidocaine should be used with caution in children younger than two years of age as there are insufficient data to support the safety and efficacy of this product in this patient population at this time. 3 WARNINGS AND PRECAUTIONS, Special Populations).
2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness. Elderly patients should be given reduced doses commensurate with their age and physical condition as they may be more sensitive to systemic effects due to increased blood levels of lidocaine following repeated doses and may require dose reductions.
EUEuropean Union· EMA
1 product
Uses
Fortacin is indicated for the treatment of primary premature ejaculation in adult men.
How to take
Drug interactions
Known interactions involving Lidocaine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 534. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 0050d05a-b8e9-c5… · revised February 8, 2024 [PDF]
- [2]MHRA (UK) · PL396990086 · revised September 13, 2024
- [3]Health Canada (DPD) · 00001961 · revised March 22, 2025
- [4]European Medicines Agency · EMEA/H/C/002693 · revised February 3, 2025
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.